Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP).
G. Sonpavde,A. Frolov,V. Macdonell,T. Hayes,M. Mims,G. Ayala,T. Wheeler,T. Thompson,M. Ittman,D. Kadmon
DOI: https://doi.org/10.1200/JCO.2009.27.15_SUPPL.5127
IF: 45.3
2009-05-20
Journal of Clinical Oncology
Abstract:5127 Background: Neoadjuvant therapy may provide an important paradigm for the discovery of active agents for the therapy of PCa. Bortezomib is a proteasome inhibitor with preclinical activity in PCa. A rationale can be made to study brief preoperative bortezomib before RP to determine feasibility and biologic activity.
METHODS
A phase II trial was designed to evaluate bortezomib 1.6mg/m2 as intravenous bolus weekly for 4 weeks followed by RP 24-72 hours after the last dose. Histological evidence of adenocarcinoma of the prostate was required with clinical stage T1c or T2a with Gleason 8-10 disease, or clinical stage T2b-T2c with Gleason grade 7 and PSA of >10 ng/mL, or clinical stage T3.
RESULTS
Accrual is complete with 40 patients enrolled, of whom 38 completed neoadjuvant bortezomib followed by RP and are evaluable. The median age was 60.2 years. No pathologic complete responses were noted. Cytopathic effects (cytolysis, nuclear pyknosis) were commonly seen compared to baseline tumor. Upregulation of apoptosis, proliferation and phosphorylated (p)-Akt have been previously reported in a subset of patients by our group (Ayala GE et al, Clin Cancer Res. 2008;14:7511-8). Two of 8 evaluable patients had a >50% decrease in serum PSA with bortezomib treatment; 3 others had PSA declines of 14%, 25%, and 45%, respectively; 1 patient had no change, and 2 displayed PSA increases. Therapy was feasible with generally manageable toxicities, and surgical morbidities did not increase. A comprehensive toxicity analysis will be presented. Feasibility of surgery, extraprostatic extension, positive margin and lymph node positive rates will be compared with matched historical controls and these data will be presented.
CONCLUSIONS
Bortezomib is feasible as neoadjuvant therapy preceding RP for PCa and demonstrates biologic activity. Given the upregulation of proliferation and pAkt, the further evaluation of bortezomib may be warranted in randomized trials in combination with chemotherapy or Akt inhibitors. [Table: see text].